Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors
Tom Farrell didn’t have much to do after Bellicum announced in January 2017 that they were bringing in a new CEO. He had led …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
